PRLD
PRLD
NASDAQ · Biotechnology

Prelude Therapeutics Inc

$3.60
+0.05 (+1.27%)
Financial Highlights (FY 2026)
Revenue
12.44M
Net Income
-101,926,440
Gross Margin
—
Profit Margin
-819.6%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — 44.6% 44.6% 44.6%
Operating Margin -861.3% 2.4% 2.2% 2.0%
Profit Margin -819.6% 2.1% 2.1% 1.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 12.44M 132.26M 127.36M 112.48M
Gross Profit — 59.02M 56.83M 50.19M
Operating Income -107,151,553 3.13M 2.80M 2.22M
Net Income -101,926,440 2.80M 2.65M 2.17M
Gross Margin — 44.6% 44.6% 44.6%
Operating Margin -861.3% 2.4% 2.2% 2.0%
Profit Margin -819.6% 2.1% 2.1% 1.9%
Rev Growth — +3.8% -1.6% +5.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 48.17M 45.92M 54.82M
Total Equity — 75.94M 77.37M 76.22M
D/E Ratio — 0.63 0.59 0.72
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -105,363,669 4.42M 4.16M 3.31M
Free Cash Flow — 2.17M 2.21M 2.87M